<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04208048</url>
  </required_header>
  <id_info>
    <org_study_id>18073011</org_study_id>
    <nct_id>NCT04208048</nct_id>
  </id_info>
  <brief_title>FLXfitTM 15 TLIF Interbody Fusion Device</brief_title>
  <official_title>Post-market Surveillance Study of FLXfitTM 15 TLIF Interbody Fusion Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is post-market, patient outcome research to evaluate medical device&#xD;
      safety and effectiveness. The data collected will assess the safety of the FLXfit 15TM&#xD;
      (studydevice) system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is post-market, patient outcome research to evaluate medical device&#xD;
      safety and effectiveness. The data collected will assess the safety of the FLXfit 15TM (study&#xD;
      device) system, as measured by the rate of serious operative and post-operative&#xD;
      complications. It will also assess the effectiveness as measured by radiographs (X-rays), CT&#xD;
      scans, MRI scans, patient-reported, health-related quality of life questionnaires up to (24)&#xD;
      months following the procedure, as compared to before surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fusion</measure>
    <time_frame>through study completion; 2 year</time_frame>
    <description>Did patient achieve fusion?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Pain Scale: Back</measure>
    <time_frame>6-week</time_frame>
    <description>0 to 10 score; higher score means worse pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Pain Scale: Back</measure>
    <time_frame>12- week</time_frame>
    <description>0 to 10 score; higher score means worse pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Pain Scale: Back</measure>
    <time_frame>6-month</time_frame>
    <description>0 to 10 score; higher score means worse pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Pain Scale: Back</measure>
    <time_frame>1-year</time_frame>
    <description>0 to 10 score; higher score means worse pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Pain Scale: Back</measure>
    <time_frame>2-year</time_frame>
    <description>0 to 10 score; higher score means worse pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Pain Scale: Leg</measure>
    <time_frame>6-week</time_frame>
    <description>0 to 10 score; higher score means worse pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Pain Scale: Leg</measure>
    <time_frame>12- week</time_frame>
    <description>0 to 10 score; higher score means worse pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Pain Scale: Leg</measure>
    <time_frame>6-month</time_frame>
    <description>0 to 10 score; higher score means worse pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Pain Scale: Leg</measure>
    <time_frame>1-year</time_frame>
    <description>0 to 10 score; higher score means worse pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Pain Scale: Leg</measure>
    <time_frame>2-year</time_frame>
    <description>0 to 10 score; higher score means worse pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>6-week</time_frame>
    <description>0 to 100 score; higher score means greater patient disability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>12- week</time_frame>
    <description>0 to 100 score; higher score means greater patient disability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>6-month</time_frame>
    <description>0 to 100 score; higher score means greater patient disability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>1-year</time_frame>
    <description>0 to 100 score; higher score means greater patient disability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>2-year</time_frame>
    <description>0 to 100 score; higher score means greater patient disability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short Form-12 Health Survey</measure>
    <time_frame>6-week</time_frame>
    <description>0 to 100 score; higher score means less patient disability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short Form-12 Health Survey</measure>
    <time_frame>12-week</time_frame>
    <description>0 to 100 score; higher score means less patient disability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short Form-12 Health Survey</measure>
    <time_frame>6-month</time_frame>
    <description>0 to 100 score; higher score means less patient disability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short Form-12 Health Survey</measure>
    <time_frame>1-year</time_frame>
    <description>0 to 100 score; higher score means less patient disability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short Form-12 Health Survey</measure>
    <time_frame>2-year</time_frame>
    <description>0 to 100 score; higher score means less patient disability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcomes Measurement Information System (PROMIS)</measure>
    <time_frame>6-week</time_frame>
    <description>20 to 80 score; higher score means higher reported self-capability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcomes Measurement Information System (PROMIS)</measure>
    <time_frame>12- week</time_frame>
    <description>20 to 80 score; higher score means higher reported self-capability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcomes Measurement Information System (PROMIS)</measure>
    <time_frame>6-month</time_frame>
    <description>20 to 80 score; higher score means higher reported self-capability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcomes Measurement Information System (PROMIS)</measure>
    <time_frame>1-year</time_frame>
    <description>20 to 80 score; higher score means higher reported self-capability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcomes Measurement Information System (PROMIS)</measure>
    <time_frame>2-year</time_frame>
    <description>20 to 80 score; higher score means higher reported self-capability</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <arm_group>
    <arm_group_label>FLXfit 15</arm_group_label>
    <description>The FLXfit 15 device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FLXfit 15TM device</intervention_name>
    <description>In order to implant the FLXfit 15TM device properly, your study doctor will first prepare the space between the low back bones (vertebrae) and then remove your damaged disc. The FLXfit 15TM device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.</description>
    <arm_group_label>FLXfit 15</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to&#xD;
        S1. Patients may also have up to Grade I spondylolisthesis or retrolisthesis at the&#xD;
        involved level(s). Patients should be skeletally mature and have completed six months of&#xD;
        non-operative treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (18-70 y/o)&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  With the following conditions of the lumbar spine as confirmed by advanced imaging (CT&#xD;
             or MRI), who is a candidate for primary spinal fusion procedure according to&#xD;
             acceptable criteria for such medical conditions:&#xD;
&#xD;
               -  Degenerative disc disease with up to Grade I spondylolisthesis&#xD;
&#xD;
               -  Spondylolisthesis&#xD;
&#xD;
          -  Failure of at least 6-months conservative treatment&#xD;
&#xD;
          -  BMI &lt; 40&#xD;
&#xD;
          -  Patient to approve no pregnancy during the 24 months of study and no participation in&#xD;
             other studies in parallel to this one&#xD;
&#xD;
          -  Ability to read, understand, and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infection, local to the operative site&#xD;
&#xD;
          -  Signs of local inflammation&#xD;
&#xD;
          -  Fever or leukocytosis&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Significant mental disorder or condition that could compromise the patient's ability&#xD;
             to remember and comply with preoperative and postoperative instructions (e.g. current&#xD;
             treatment for a psychiatric/psychosocial disorder, senile dementia, Alzheimer's&#xD;
             disease, traumatic head injury)&#xD;
&#xD;
          -  Prior surgical procedure (with the exception of decompression only procedure) at the&#xD;
             index level(s) using the desired operative approach&#xD;
&#xD;
          -  Prior fusion procedure at an adjacent level&#xD;
&#xD;
          -  Any other condition which would preclude the potential benefit of spinal implant&#xD;
             surgery, such as the presence of tumors or congenital abnormalities, fracture local to&#xD;
             the operating site, elevation of segmentation rate unexplained by other diseases,&#xD;
             elevation of white blood count (WBC), or a marked left shift in the WBC differential&#xD;
             count&#xD;
&#xD;
          -  Neuromuscular disorder that would engender unacceptable risk of instability, implant&#xD;
             fixation failure, or complications in postoperative care&#xD;
&#xD;
          -  Active local infection in or near the operative region&#xD;
&#xD;
          -  Active systemic infection and/or disease&#xD;
&#xD;
          -  Severe osteoporosis or insufficient bone density, which in the medical opinion of the&#xD;
             physician precludes surgery or contraindicates instrumentation&#xD;
&#xD;
          -  Endocrine or metabolic disorders known to affect osteogenesis (e.g. Paget's disease,&#xD;
             renal osteodystrophy, hypothyroidism)&#xD;
&#xD;
          -  Systemic disease that requires the chronic administration of nonsteroidal anti-&#xD;
             inflammatory or steroidal drugs&#xD;
&#xD;
          -  Suspected or documented allergy or intolerance to implant's materials&#xD;
&#xD;
          -  Symptomatic cardiac disease&#xD;
&#xD;
          -  Patient unwilling to cooperate with postoperative instructions.&#xD;
&#xD;
          -  Any case where the implant components selected for use would be too large or too small&#xD;
             to achieve a successful result.&#xD;
&#xD;
          -  Patient having inadequate tissue coverage over the operative site or inadequate bone&#xD;
             stock or quality.&#xD;
&#xD;
          -  Any patient in which implant utilization would interfere with anatomical structures or&#xD;
             expected physiological performance.&#xD;
&#xD;
          -  Prior fusion at the level to be treated.&#xD;
&#xD;
          -  Back VAS &lt; 4/10&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 6, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Kern Singh, MD</investigator_full_name>
    <investigator_title>Attending Orthopedic Surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All study related documents will be shared through a password protected and encrypted program managed by Midwest Orthopedics IT department.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The data will become available after the participant has signed the informed consent and will remain available until the study is closed.</ipd_time_frame>
    <ipd_access_criteria>The study staff will have to complete HIPPA and confidentiality training. In addition, they must by Midwest Orthopedics staff who will access the information on a password protected and encrypted computer.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT04208048/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

